Notes: Feb. 04, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced a one-for-ten reverse stock split of its shares of common stock. Stockholders of ContraFect approved an amendment to the Company’s Certificate of Incorporation to effect the reverse stock split at a Special Meeting of Stockholders held on January 31, 2020. The reverse stock split is intended to give ContraFect greater flexibility in considering and planning for future potential business needs and to increase the per share trading price \of the Company’s common stock to satisfy the $1.00 minimum price requirement for continued listing on The Nasdaq Capital Market. At approximately 5:45 p.m., Eastern Time, on February 3, 2020, the Company filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect the reverse stock split with the Secretary of State of the State of Delaware. The reverse stock split became effective immediately upon the filing of the Certificate of Amendment. At the opening of trading on February 4, 2020, ContraFect expects its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market under the symbol “CFRX” and under a new CUSIP number 212326300.